Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Trial Details

NCT ID

NCT05725200

Phase

PHASE2

Sponsor

Oslo University Hospital

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Alectinib
Cetuximab
Crizotinib
Dasatinib
Everolimus
Encorafenib

Locations (sample)

Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

Has a histologically-proven locally advanced or metastatic adenocarcinoma from colon or rectum
Has received or is receiving systemic treatment for mCRC
Has non-resectable metastases and eligible to undergo a radiological-guided core biopsy from at least one metastasis
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →